2024-519565-21-01RecruitingPhase 3
Effects of combined diuretic therapy on exercise capacity, alveolar-capillary diffusion and maintenance of euvolemia in chronic congestive heart failure, diuretic therapy compared with loop diuretics and potassium-sparing diuretics
Source: EU CTIS (euclinicaltrials.eu) · Last updated 18 Dec 2025
Brief summary (registry, in English)
To compare two different treatment strategies (control arm treated with loop diuretic and potassium sparing and experimental arm that will combine such therapy with acetazolamide and free-dose metolazone) in patients with chronic heart failure.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- First submitted
- 23 Jan 2025
- Start date
- 21 Sept 2023
- Lead sponsor
- Centro Cardiologico Monzino S.p.A.
- Diseases
- Heart failure
- EU CT number
- 2024-519565-21-01
- EudraCT number
- 2022-003314-37
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 44
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with long-term heart failure who left hospital after a worsening of their heart failure. It compares two water-pill (diuretic) treatment plans.
- Age
- 18 to 80 years (the exclusion list also names under 18 or over 85 years).
- Sex
- Women and men can join.
- Disease stage
- Long-term (chronic) heart failure, with reduced or preserved pumping function. At least a second worsening (decompensation) needing hospital care in the past 12 months, and discharged after the latest hospital stay.
- Earlier treatment
- Taking a loop diuretic (water pill) at the dose of furosemide 40 mg (or equivalent) or higher at the time of hospital admission.
Main reasons for not taking part
- Severe narrowing of the aortic valve (severe aortic stenosis)
- Severe kidney failure (eGFR below 20 ml/min/1.73m2)
- Severe low blood sodium (severe hyponatremia)
- Heart failure medicines already optimized during the hospital stay
- Current pregnancy or breastfeeding in women who could have children
Read by machine on 9 Nov 2026.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other illness
- Medical therapy for heart failure optimized during hospitalization
Lab values
- patients with severe renal failure (eGFR<20 ml/min/1.73m2 according to CockroftGault)
Age
- age <18 years or >85 years
Other
- patients with severe aortic stenosis
- patients with severe hyponatremia
- Documented current pregnancy and lactating status in women of childbearing potential
Who the study is looking for
- written informed consent signed
- Age: 18-80
- Patients with chronic heart failure (at reduced or preserved ejection fraction)
- Patients discharged after hospitalization for acute heart failure (at least second episode of decompensation in the past 12 months)
- Patients being treated with loop diuretics at the same or higher dosage of furosemide 40 mg (or equivalent) at the time of admission
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centro Cardiologico Monzino S.p.A. | Milan | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.